Kawaljit Kaur serves as the Associate Vice President of MPN Life-Cycle Planning and Portfolio Strategy at Incyte, where she leverages her extensive experience in the pharmaceutical industry to drive strategic initiatives within the myeloproliferative neoplasms (MPN) portfolio. With a robust background in hematology and oncology,...
Kawaljit Kaur serves as the Associate Vice President of MPN Life-Cycle Planning and Portfolio Strategy at Incyte, where she leverages her extensive experience in the pharmaceutical industry to drive strategic initiatives within the myeloproliferative neoplasms (MPN) portfolio. With a robust background in hematology and oncology, Kawaljit has successfully led cross-functional teams in the development and commercialization of innovative therapies, ensuring that they meet the evolving needs of patients and healthcare providers alike. Her expertise spans multiple therapeutic areas, including anti-infectives, HIV, hepatitis, and cardiovascular health, allowing her to bring a comprehensive perspective to her current role.
At Incyte, Kawaljit is instrumental in shaping the life-cycle management strategies for MPN products, focusing on both pre-launch activities and ongoing market access efforts. She has spearheaded key projects that involve strategic planning and execution across diverse geographies, including global markets, the Asia-Pacific region, and select Southeast Asian countries. Her ability to navigate complex regulatory environments and foster collaboration among sales, marketing, and operational teams has resulted in successful product launches and sustained market growth.
Kawaljit’s leadership style emphasizes the importance of data-driven decision-making and innovative marketing strategies, which have proven essential in enhancing sales effectiveness and optimizing portfolio performance. As a thought leader in the pharmaceutical space, she continues to advocate for patient-centric approaches in drug development, ensuring that Incyte remains at the forefront of addressing unmet medical needs in the MPN landscape. Her commitment to excellence and strategic foresight positions her as a key player in shaping the future of hematology treatments.
